HUMA vs LMAT
HUMA: Humacyte engineers acellular tissue-based blood vessels (ATEVs) for vascular access and other applications, with its lead product Symvess in late-stage clinical development. LMAT: LeMaitre Vascular develops specialized medical devices and tissue-based solutions for vascular and cardiovascular surgery, targeting an aging population with peripheral vascular disease.
Side-by-side fundamentals
| Metric | HUMA | LMAT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $0.64 | $98.81 | |
| Market cap as of 2026-07-23 | $174M | $2.3B | |
| P/E as of 2026-07-23 | n/a | 36.84 | |
| PEG as of 2026-07-23 | n/a | 1.00 | |
| Net margin as of 2026-07-23 | -3494.6% | +24.4% | LMAT higher |
| Gross margin as of 2026-07-23 | -563.6% | +72.4% | LMAT higher |
| Operating margin as of 2026-07-23 | -6205.7% | +28.5% | LMAT higher |
| ROE as of 2026-07-23 | -1278.9% | +16.2% | LMAT higher |
| ROA as of 2026-07-23 | -85.4% | +10.3% | LMAT higher |
| Debt / equity as of 2026-07-23 | 5.67 | 0.42 | LMAT lower |
| Revenue growth (YoY) as of 2026-07-23 | +231.7% | +13.3% | HUMA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +15.6% | |
| Dividend yield as of 2026-07-23 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 2.56 | 0.54 | |
| 1-year return as of 2026-07-22 close | -70.8% | +22.9% | LMAT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.